Pharmacokinetic investigation of imatinib using accelerator mass spectrometry in patients with chronic myeloid leukemia

To investigate the potential use of accelerator mass spectrometry (AMS) in the study of the clinical pharmacology of imatinib. Six patients who were receiving imatinib (400 mg/d) as part of their ongoing treatment for chronic myeloid leukemia (CML) received a dose containing a trace quantity (13.6 k...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research Jg. 13; H. 14; S. 4164
Hauptverfasser:	Boddy, Alan V, Sludden, Julieann, Griffin, Melanie J, Garner, Colin, Kendrick, John, Mistry, Pritesh, Dutreix, Catherine, Newell, David R, O'Brien, Stephen G
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States 15.07.2007
Schlagworte:	Adult Antineoplastic Agents - pharmacokinetics Antineoplastic Agents - therapeutic use Benzamides Female Humans Imatinib Mesylate Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Male Mass Spectrometry Middle Aged Particle Accelerators Piperazines - pharmacokinetics Piperazines - therapeutic use Polymerase Chain Reaction Pyrimidines - pharmacokinetics Pyrimidines - therapeutic use
ISSN:	1078-0432
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!